Categories Consumer, Earnings

Tapestry stock jumps on Q3 earnings beat and $1 billion share buyback plan

Tapestry’s (NYSE: TPR) Q3 earnings surpassed market expectations, while revenue fell short of the estimates. Shares of Tapestry soared about 15% in the pre-market trading hours due to the earnings beat and the company’s announcement of $1 billion share repurchase plan. Tapestry reported earnings of $0.42 per share on revenue of $1.33 billion. Analysts had expected the company to post earnings of $0.41 per share on revenue of $1.34 billion.

Commenting on the $1 billion stock buyback plan, CEO Victor Luis said, “We’re also excited to announce the approval of a $1 billion share repurchase authorization, demonstrating our confidence in driving long-term, sustainable growth and value.”

Tapestry (TPR) Q3 2019 earnings infograph

On a GAAP basis, Tapestry’s net income decreased to $117.4 million or $0.40 per share in Q3 from income of $140.3 million or $0.48 per share in the prior year quarter. On a constant currency basis, sales from Coach, Kate Spade and Stuart Weitzman brands, increased 1%, 5% and 4%, respectively. On a reported basis, Coach sales was down slightly, while Kate Spade and Stuart Weltzman rose 4% and 2%, respectively.

Tapestry expects to deliver positive comps at both Coach and Kate Spade along with profitability improvements at Stuart Weitzman, both in the fourth fiscal quarter and in the years ahead. The company maintained its EPS guidance for fiscal 2019 and outlook for double-digit operating income and EPS growth in fiscal 2020.

The New York-based retailer expects fiscal 2019 revenues to increase at a low-to-mid-single-digit rate from fiscal 2018. Non-GAAP earnings per share is expected to be in the range of $2.55 to $2.60.

Tapestry stock, which plunged to a 52-week low ($30.05) last month, had declined 9% since the beginning of this year and dropped 32% in the past 52 weeks.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

 

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top